Molecular Stating of Prostate Cancer. II. A Comparison of the Application of an Enhanced Reverse Transcriptase Polymerase Chain Reaction Assay for Prostate Specific Antigen Versus Prostate Specific Membrane Antigen

Abstract

No AccessJournal of UrologyClinical Urology: Original Article1 May 1995Molecular Stating of Prostate Cancer. II. A Comparison of the Application of an Enhanced Reverse Transcriptase Polymerase Chain Reaction Assay for Prostate Specific Antigen Versus Prostate Specific Membrane Antigen Cristoforo Cama, Carl A. Olsson, Anthony J. Raffo, Harris Perlman, Ralph O'Toole Buttyan, Kathleen Don McMahon, Mitchell C. Benson, and Aaron E. Katz Cristoforo CamaCristoforo Cama More articles by this author , Carl A. OlssonCarl A. Olsson More articles by this author , Anthony J. RaffoAnthony J. Raffo More articles by this author , Harris PerlmanHarris Perlman More articles by this author , Ralph O'Toole ButtyanRalph O'Toole Buttyan More articles by this author , Don McMahonDon McMahon More articles by this author , Mitchell C. BensonMitchell C. Benson More articles by this author , and Aaron E. KatzAaron E. Katz More articles by this author View All Author Informationhttps://doi.org/10.1016/S0022-5347(01)67407-XAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Current imaging modalities used to stage prostate cancer clinically fail to detect extracapsular disease in a significant subset of patients. A molecular based peripheral blood assay using the reverse transcriptase polymerase chain reaction has recently been shown to be a highly sensitive staging modality for detecting extraprostatic disease preoperatively. The assay uses primers that are specific for prostate specific antigen (PSA). We compare the application of the reverse transcriptase polymerase chain reaction assay using primers specific for the human prostate specific membrane antigen with results obtained from the same specimens by reverse transcriptase polymerase chain reaction for PSA. Prostate specific membrane antigen, a recently cloned prostatic antigen, is a transmembrane glycoprotein that has been described as prostate specific. These assays were applied to ribonucleic acids extracted from the peripheral blood lymphocyte fraction of 80 patients with clinically localized prostate cancer. In addition, blood specimens from 20 female patients, 20 young male patients, 25 age-matched control men under treatment for benign prostatic hypertrophy and 20 men with established, untreated metastatic prostate cancer were tested. All 3 groups of noncancer patients had negative polymerase chain reactions for PSA as well as prostate specific membrane antigen. Of 20 metastatic prostate cancer patients 16 (80 percent) had positive polymerase chain reactions for PSA, while only 10 (50 percent) had positive results for prostate specific membrane antigen. Among the 80 patients with clinically localized disease (stages T1 to T2cNOMO), 27 and 19 had positive polymerase chain reaction for PSA and prostate specific membrane antigen, respectively, from blood specimens obtained preoperatively. Analyzing the final pathology in each patient with the reverse transcriptase polymerase chain reaction assay identified a significantly stronger correlation with tumor invasion using the results of the PSA test rather than the results of the prostate specific membrane antigen reverse transcriptase polymerase chain reaction test (67 percent versus 34 percent sensitivity for detecting capsular penetration, 87 percent versus 46 percent sensitivity for detecting disease to the surgical margin and 83 percent versus 16 percent sensitivity for detecting seminal vesicle invasion). In contrast to the reverse transcriptase polymerase chain reaction assay for PSA, a similar assay done for prostate specific membrane antigen did not correlate with pathological stage of prostate cancer. References 1 : Early detection of prostate cancer; a molecular overview.. In: Early Detection of Cancer: Molecular Markers. Edited by . New York: Futura Publishing Co.1994: 191. chapt. 19. Google Scholar 2 : Influence of capsular penetration on progression following radical prostatectomy: a study of 196 cases with long-term followup.. J. Urol.1993; 150: 135. Abstract, Google Scholar 3 : Correlation of pathologic findings after radical retropubic prostatectomy.. Cancer1993; 71: 3582. Google Scholar 4 : An assessment of radical prostatectomy. Time trends, geographic variation, and outcomes. The Prostate Patient Outcomes Research Team.. J.A.M.A.1993; 269: 2633. Google Scholar 5 : Postoperative radiotherapy for patients with carcinoma of the prostate undergoing radical prostatectomy with positive surgical margins, seminal vesicle involvement and/or penetration through the capsule.. J. Urol.1987; 138: 1407. Abstract, Google Scholar 6 : Morphologic analysis of surgical margins with positive findings in prostatectomy for adenocarcinoma of the prostate.. Cancer1992; 69: 520. Google Scholar 7 : Nerve-sparing radical prostatectomy: extraprostatic tumor extension and preservation of erectile function.. J. Urol1985; 134: 1149. Abstract, Google Scholar 8 : Molecular staging of prostate cancer with the use of an enhanced reverse transcriptase-PCR assay.. Urology1994; 43: 765. Google Scholar 9 : Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen.. Cancer Res.1993; 53: 227. Google Scholar 10 : Monoclonal antibodies to a new antigenic marker in epithelial cells and serum of prostatic cancer patients.. Anticancer Res.1987; 7: 927. Google Scholar 11 : Expression of the prostate-specific membrane antigen.. Cancer Res.1994; 54: 1807. Google Scholar 12 Prostate carcinoma.. Clinical TNM Classification and Staging.. : American Joint Committee on Cancer (AJCC)/International Union Against Cancer (UICC)1992. Google Scholar 13 : LNCaP model of human prostatic carcinoma.. Cancer Res.1983; 43: 1809. Google Scholar 14 : Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction.. Ann. Biochem.1987; 162: 156. Google Scholar 15 : DNA sequencing with chain-terminating inhibitors.. Proc. Natl. Acad. Sci.1977; 74: 5483. Google Scholar 16 : Genomic sequences of human prostate specific antigen (PSA).. Nucleic Acids Res.1989; 17: 3981. Google Scholar 17 : Molecular Cloning: A Laboratory Manual. Cold Springs Harbor, New York: Cold Springs Harbor Press1989: 810. Google Scholar 18 : Circulating prostate specific antigen-positive cells correlate with metastatic prostate cancer.. Brit. J. Urol.1992; 69: 392. Google Scholar 19 : Detection of hematogenous micrometastasis in patients with prostate cancer.. Cancer Res.1992; 52: 6110. Google Scholar 20 : Preclinical results and human immunohistochemical studies with sup 90Y-CYT-356: a new prostate cancer therapeutic agent. J. Urol.1992; 147: 361A. part 2, abstract 596. Google Scholar 21 : Antigens up-regulate the human prostate-specific antigen messenger ribonucleic acid (mRNA), but down regulate the prostatic acid phosphatase mRNA in the LNCaP cell line.. Endocrinology1992; 130: 766. Google Scholar 22 : Transcriptional regulation of prostate kallikrein-like genes by androgen.. Molec. Endocr.1992; 6: 753. Google Scholar From the Department of Urology and Pathology, Columbia University, College of Physicians and Surgeons, New York and Division of Urology, Maimonides Medical Center, Brooklyn, New York.© 1995 by American Urological Association, Inc.FiguresReferencesRelatedDetailsCited byHARA I, YAMADA Y, MIYAKE H, HARA S, GOTOH A, FUJISAWA M, OKADA H, ARAKAWA S and KAMIDONO S (2018) DETECTION OF β-HUMAN CHORIONIC GONADOTROPIN EXPRESSING CELLS BY NESTED REVERSE TRANSCRIPTASE-POLYMERASE CHAIN REACTION IN THE PERIPHERAL BLOOD STEM CELLS OF PATIENTS WITH ADVANCED GERM CELL TUMORJournal of Urology, VOL. 167, NO. 3, (1487-1491), Online publication date: 1-Mar-2002.Okegawa T, Nutahara K and Higashihara E (2018) DETECTION OF MICROMETASTATIC PROSTATE CANCER CELLS IN THE LYMPH NODES BY REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION IS PREDICTIVE OF BIOCHEMICAL RECURRENCE IN PATHOLOGICAL STAGE T2 PROSTATE CANCER.Journal of Urology, VOL. 163, NO. 4, (1183-1188), Online publication date: 1-Apr-2000.THEODORESCU D, FRIERSON H and SIKES R (2018) MOLECULAR DETERMINATION OF SURGICAL MARGINS USING FOSSA BIOPSIES AT RADICAL PROSTATECTOMYJournal of Urology, VOL. 161, NO. 5, (1442-1448), Online publication date: 1-May-1999.Lintula S and Stenman U (2018) The Expression of Prostate-Specific Membrane Antigen in Peripheral Blood LeukocytesJournal of Urology, VOL. 157, NO. 5, (1969-1972), Online publication date: 1-May-1997.Cama C, Olsson C, Buttyan R, De Vries G, Wise G and Katz A (2018) Molecular Staging of Prostate Cancer. III. Effects of Cystoscopy and Needle Biopsy on the Enhanced Reverse Transcriptase Polymerase Chain Reaction AssayJournal of Urology, VOL. 157, NO. 5, (1748-1751), Online publication date: 1-May-1997.Olsson C, de Vries G, Raffo A, Benson M, O'Toole K, Cao Y, Buttyan R and Katz A (2018) Preoperative Reverse Transcriptase Polymerase Chain Reaction for Prostate Specific Antigen Predicts Treatment Failure Following Radical ProstatectomyJournal of Urology, VOL. 155, NO. 5, (1557-1562), Online publication date: 1-May-1996. Volume 153Issue 5May 1995Page: 1373-1378 Advertisement Copyright & Permissions© 1995 by American Urological Association, Inc.MetricsAuthor Information Cristoforo Cama More articles by this author Carl A. Olsson More articles by this author Anthony J. Raffo More articles by this author Harris Perlman More articles by this author Ralph O'Toole Buttyan More articles by this author Don McMahon More articles by this author Mitchell C. Benson More articles by this author Aaron E. Katz More articles by this author Expand All Advertisement PDF downloadLoading ...